• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.

作者信息

Galvis Virgilio, Spinelli Francesca Romana, Tello Alejandro, Sossa Claudia L, Higuera Juan D, Gómez Edgar D, Serrano Sergio E, Camacho Paul A, Velez Federico G

机构信息

Centro Oftalmológico Virgilio Galvis, Floridablanca, Colombia.

Fundación Oftalmológica de Santander FOSCAL, Floridablanca, Colombia.

出版信息

Arch Bronconeumol (Engl Ed). 2020 Sep;56(9):606-608. doi: 10.1016/j.arbr.2020.05.010. Epub 2020 Sep 14.

DOI:10.1016/j.arbr.2020.05.010
PMID:33994644
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7489223/
Abstract
摘要

相似文献

1
Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.羟氯喹作为新型冠状病毒SARS-CoV-2感染的预防用药：正在进行的临床试验综述
Arch Bronconeumol (Engl Ed). 2020 Sep;56(9):606-608. doi: 10.1016/j.arbr.2020.05.010. Epub 2020 Sep 14.
2
Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis.使用羟氯喹预防 SARS-CoV-2 感染和治疗轻症 COVID-19：系统评价和荟萃分析。
J Bras Pneumol. 2021 Oct 15;47(5):e20210236. doi: 10.36416/1806-3756/e20210236. eCollection 2021.
3
Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection.解读羟氯喹预防对严重急性呼吸综合征冠状病毒2感染的影响。
Indian J Med Res. 2021 May;153(5&6):564-565. doi: 10.4103/ijmr.ijmr_1092_21.
4
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
5
Current pharmacological treatments for SARS-COV-2: A narrative review.新型冠状病毒肺炎的当前药物治疗：一篇叙述性综述。
Eur J Pharmacol. 2020 Sep 5;882:173328. doi: 10.1016/j.ejphar.2020.173328. Epub 2020 Jun 27.
6
Dose-Response Effects of Hydroxychloroquine on Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection.羟氯喹对预防严重急性呼吸综合征冠状病毒2感染的剂量反应效应
Clin Infect Dis. 2021 Oct 5;73(7):e1771-e1772. doi: 10.1093/cid/ciaa1807.
7
Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?羟氯喹联合阿奇霉素是否仍将成为 COVID-19 的游戏规则改变者？
Front Immunol. 2020 Aug 7;11:1969. doi: 10.3389/fimmu.2020.01969. eCollection 2020.
8
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病（NO COVID-19）实用开放性标签研究，评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
9
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.仓促下结论？有关羟氯喹治疗 COVID-19 的快速报告和结果传播及其后果。
Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30.
10
An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19.一项关于新冠病毒疾病羟氯喹治疗试验的独立评估与重新分析。
Swiss Med Wkly. 2020 Apr 29;150:w20262. doi: 10.4414/smw.2020.20262. eCollection 2020 Apr 20.

引用本文的文献

1
Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection.医护人员血清调查为羟氯喹预防 SARS-CoV-2 感染的有效性提供了支持性证据。
J Epidemiol Glob Health. 2021 Sep;11(3):283-288. doi: 10.2991/jegh.k.210518.001. Epub 2021 May 23.
2
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study.伊维菌素在预防印度医护人员感染 SARS-CoV-2 中的作用：一项匹配病例对照研究。
PLoS One. 2021 Feb 16;16(2):e0247163. doi: 10.1371/journal.pone.0247163. eCollection 2021.
3
Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests.意大利一家养老院在 COVID-19 大流行期间的死亡率：与性别、年龄、ADL、维生素 D 补充剂和诊断测试限制的相关性。
Aging (Albany NY). 2020 Dec 22;12(24):24522-24534. doi: 10.18632/aging.202307.
4
Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.在 SARS-CoV-2（COVID-19）紧急情况下预防耳毒性。
J Glob Antimicrob Resist. 2020 Dec;23:263-264. doi: 10.1016/j.jgar.2020.09.030. Epub 2020 Oct 17.
5
Thoughts From the Trenches: Should We Look at the "Healthy"?战壕中的思考：我们是否应该关注“健康人群”？
Front Public Health. 2020 Sep 9;8:490. doi: 10.3389/fpubh.2020.00490. eCollection 2020.
6
Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.氯喹和羟氯喹治疗 COVID-19：重新利用失败的观点。
J Clin Pharm Ther. 2021 Feb;46(1):17-27. doi: 10.1111/jcpt.13267. Epub 2020 Sep 27.
7
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.羟氯喹在新冠大流行时代：为了合理预防 SARS-CoV-2 感染而进行的探索。
Expert Rev Anti Infect Ther. 2021 Jan;19(1):5-16. doi: 10.1080/14787210.2020.1799785. Epub 2020 Aug 16.

本文引用的文献

1
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?在长期护理医院，COVID-19 的暴露后预防可否被视为疫情应对策略？
Int J Antimicrob Agents. 2020 Jun;55(6):105988. doi: 10.1016/j.ijantimicag.2020.105988. Epub 2020 Apr 17.
2
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).氯喹和羟氯喹在冠状病毒病-19（COVID-19）中的预防作用的系统评价。
Int J Rheum Dis. 2020 May;23(5):613-619. doi: 10.1111/1756-185X.13842. Epub 2020 Apr 27.
3
Off-label prescribing in the midst of a pandemic: The case of hydroxychloroquine.大流行期间的超说明书用药：羟氯喹啉的案例。
Aust J Gen Pract. 2020 Apr 8;49. doi: 10.31128/AJGP-COVID-06.
4
Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China.公共卫生干预措施与中国武汉 COVID-19 疫情流行病学的关联。
JAMA. 2020 May 19;323(19):1915-1923. doi: 10.1001/jama.2020.6130.
5
Covid-19: four fifths of cases are asymptomatic, China figures indicate.中国数据显示，新冠疫情：五分之四的病例无症状。
BMJ. 2020 Apr 2;369:m1375. doi: 10.1136/bmj.m1375.
6
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.在严重急性呼吸综合征冠状病毒2（新冠病毒）大流行中是否将抗疟药作为一种预防性干预措施加以考虑。
Ann Rheum Dis. 2020 May;79(5):666-667. doi: 10.1136/annrheumdis-2020-217367. Epub 2020 Apr 2.
7
Emerging prophylaxis strategies against COVID-19.针对新型冠状病毒肺炎的新兴预防策略。
Monaldi Arch Chest Dis. 2020 Mar 30;90(1). doi: 10.4081/monaldi.2020.1289.
8
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?氯喹抗冠状病毒的抗病毒作用的新见解：对 COVID-19 有何期待？
Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.
9
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
10
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.氯喹和羟氯喹作为对抗新型冠状病毒肺炎的现有武器。
Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.